Fig. 1: Trial profile.

Study profile showing the allocation of participants to three dosage groups: Group 1, low dose at 5 × 10⁹ vp, Group 2 intermediate dose at 2.5 × 10¹⁰ vp, and Group 3 high dose at 5 × 10¹⁰ vp. None of the 24 recruited participants were lost in follow-up.